TABLE 1.
BASELINE CHARACTERISTICS OF PARTICIPANTS ENROLLED INTO THE TRIAL
| Abatacept (n = 13) | Placebo (n = 11) | P Value | |
| Age (range) | 35 ± 9.8 (20–47) | 28 ± 7.8 (19–42) | 0.08 |
| Sex | 0.34 | ||
| Female | 7 (54%) | 8 (73%) | |
| Male | 6 (46%) | 3 (27%) | |
| Race | 0.13 | ||
| White | 8 (62%) | 5 (45%) | |
| African American | 5 (38%) | 3 (28%) | |
| Mixed | 0 | 3 (27%) | |
| Inhaled corticosteroids (number receiving) | 3 | 2 | 0.77 |
| FEV1, L | 3.19 ± 0.92 | 3.05 ± 0.81 | 0.71 |
| FEV1, % predicted | 89.1 ± 12.3 | 87.4 ± 14.9 | 0.81 |
| PC20, mg/ml | 5.00 ± 10.52 | 1.46 ± 2.12 | 0.29 |
| IgE, mg/ml | 313.2 ± 339 | 312 ± 302 | 0.79 |
| Allergen | 0.20 | ||
| Cat | 7 (54%) | 3 (27%) | |
| Ragweed | 6 (46%) | 5 (45%) | |
| Dermatophagoides farina | 0 | 2 (18%) | |
| Dermatophagoides pternyssinus | 0 | 1 (9%) |
Definition of abbreviations: PC20 = provocative concentration of methacholine sufficient to induce a 20% decline in FEV1.
For FEV1, PC20, and IgE, the data are presented as mean ± standard deviation.